세계의 노인황반변성(AMD) 치료제 시장 : 제품별, 분자별, 승인 유형별, AMD 유형별, 최종사용자별 - 예측(-2029년)

The Age-Related Macular Degeneration (AMD) Drugs market is projected to reach USD 17.37 Billion from 2029 USD 10.46 Billion in 2024 growing at a CAGR of 10.7% during the forecast period of 2024-2029.

Major pharmaceutical companies have reported a 2 fold increase in the geriatric population (above 60 years of age) by 2050, and this increase will have an impact on the number of AMD cases as AMD is associated with old age. Lifestyle factors such as smoking, diet, and physical activity also significantly influence AMD risk. For instance, studies have shown that smoking can accelerate the onset of AMD by an average of 5.5 years. According to the Macular Society (UK), smokers are likely to develop AMD up to 10 years earlier than non-smokers. Leading ophthalmologists from the UAE and UK have reported a decrease in the onset age of AMD and concluded that unhealthy lifestyle habits can bring down this age further by the next decade. Researchers from Japan conducted research to examine the effects of alcohol on AMD and concluded that moderate to heavy alcohol consumption increases the risk of early AMD. Similarly, a higher body mass index (BMI) is associated with an increased risk of both early and late AMD, as obesity and lack of physical activity are linked to increased oxidative stress and inflammation, contributing to AMD development. Rising incidences of AMD are driving companies to expand their drug pipeline and seek fast-track designations to advance their products' availability. For instance, in 2021 Opthea Limited received fast-track designation for its pipeline drug OPT-302 developed for the treatment of patients with wet AMD, advancing its development process. Similarly in 2023, Adverum Biotechnology received an Innovation Passport from the UK's MHRA for its pipeline drug Ixo-vec (ixoberogene soroparvovec), helping to speed up patient access and regulatory support in the UK. These developments along with a rising number of AMD cases are projected to increase the demand for AMD drugs in the market.

"Vabysmo drug is set to register the highest growth during 2024-2029 in the Age-Related Macular degeneration (AMD) drugs market"

Based on products the Age-Related Macular Degeneration (AMD) drugs market is segmented into Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, and other products including Beovu, Conbercept, Byooviz, and Izervay among others. Vabysmo (faricimab-svoa) is set to register the highest growth rate during the forecast period of 2024-2029, owing to the positive feedback received from patients and ophthalmologists for the treatment of AMD. The rising adoption of the drug is also supported by the 4x increase in the revenue of the drug from 2022 to 2023. Studies conducted to test the efficacy and tolerability of the drug have concluded that the drug is well tolerated in people with retinal disorders and can preserve vision while reducing the frequency of injections elevating the treatment burden of the patients. The drug is also used for the treatment of patients who showed resistance to the treatment from Eylea (aflibercept) and has significant improvement in visual acuity.

"Hospitals to witness the high growth in the AMD drugs market by End User"

Based on end users, the age-related macular degeneration (AMD) drugs market is segmented into hospitals, specialty centers, and long-term care facilities. Hospitals are projected to witness the highest growth rate during the forecast period of 2024-2029. This growth can be attributed to factors such as the ability of hospitals to provide comprehensive care to patients through advanced healthcare infrastructure and specialized treatment facilities. Additionally, hospitals are more abundant than any other end user (Specialty centers and Long-term care facilities) and modern hospitals are generally multispeciality in nature offering specialized treatment. Hospitals often collaborate with long-term care (LTC) facilities to provide support such as ophthalmologists for the treatment of individuals living in the care facility. Moreover, hospitals also partner with pharmaceutical companies to ensure an optimal supply of AMD drugs for the patients.

"Biologics segment accounted for the highest growth rate in the Age-Related Macular Degeneration (AMD) drugs market by approval type"

Based on approval type, the age-related macular degeneration (AMD) drugs market is segmented into biologics and biosimilars. During the forecast period of 2024-2029, biologics are projected to register the highest growth in the AMD drugs market by approval type. This high growth can be attributed to the increase in the number of approvals for biologics such as Vabysmo, Eylea HD, Syfovre, and Izervay, among others, for the treatment of AMD. Moreover, as these drugs are recently approved they are protected by patents and generally prevent biosimilar entry into the market. Additionally, improved reimbursement policies and comprehensive insurance coverage offered for biologics generally deter patients and ophthalmologists from choosing biosimilars over biologics. New innovative companies are also developing novel biologics for treating various forms of AMD supporting the growth of this segment.

"North America: The fastest-growing country in the Age-Related Macular Degeneration (AMD) drugs market"

The Age-Related Macular Degeneration (AMD) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is projected to register the highest CAGR during the forecast period. Factors such as rising AMD cases due to an increase in the geriatric population and accompanied by unhealthy lifestyle and dietary habits, and increasing pharmaceutical R&D spending, by major pharmaceutical and biotechnology companies present in the region, to develop novel therapies and drug delivery systems for AMD disease are driving the growth of AMD drugs in the region. Additionally, growing public-private partnerships, increasing government support and improved reimbursement policies further support the growth of the AMD drugs market in this region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side -70% and Demand Side - 30%
• By Designation: Managers -45%, CXOs and Directors -30%, and Executives - 25%
• By Region: North America-35%, Europe -25%, Asia-Pacific -15%, Latin America-10%, Middle East-10% and Africa-5%

Lists of Companies Profiled in the Report:

• Regeneron Pharmaceuticals Inc. (US)
• Bayer AG (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Apellis Pharmaceuticals (US)
• Coherus BioSciences (US)
• Astellas Pharma Inc. (Japan)
• Biogen (US)
• STADA Arzneimittel AG (Germany)
• Formycon AG (Germany)
• Biocon. (India)
• Outlook Therapeutics, Inc. (US)
• Intas Pharmaceuticals Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Chengdu Kanghong Biotech Company (China)
• Sandoz Group AG (Switzerland)
• Stealth BioTherapeutics Inc. (US)
• Ocular Therapeutix, Inc. (US)
• Opthea Limited (Australia)
• Kodiak Sciences Inc. (US)
• Innovent Biologics, Inc. (China)
• Bio-Thera Solution (China)
• Alvotech (Iceland)
• Alteogen Inc. (South Korea)
• Shanghai Henlius Biotech, Inc. (China)
• Amgen Inc. (US)
• Ocumension Therapeutics. (China)
• Adverum Biotechnologies, Inc. (US)

Research Coverage:

This report provides a detailed picture of the age-related macular degeneration (AMD) drugs market. It aims at estimating the size and future growth potential of the market across different segments, such as products, molecules, type of AMD, approval type, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Reasons to Buy the Report:

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing risk of AMD due to changing lifestyle and dietary habits, Steady development and approvals of drugs and Favorable reimbursement and insurance policies), restraints (Off-Label Use of Drugs), opportunities (Shifting Focus on New Drug Modalities, Rapidly expanding market in developing countries, Need to address dry age-macular degeneration and geographic atrophy), and challenges (Non-adherence to treatments) influencing the growth of the Age-Related Macular Degeneration (AMD) durgs market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new therapy launches in the Age-Related Macular Degeneration (AMD) drugs market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various opportunities and developments across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Age-Related Macular Degeneration (AMD) drugs market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players like Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Novartis AG (Switzerland) among others in the Age-Related Macular Degeneration (AMD) drugs market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS AND EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 MARKETS COVERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION DRUGS MARKET

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
• 2.3 MARKET GROWTH FORECAST
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW
• 4.2 NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023
• 4.3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION)
• 4.4 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023
• 4.5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Changing lifestyle and dietary habits
    • 5.2.1.2 Steady development and approvals of drugs
    • 5.2.1.3 Favorable reimbursement and insurance policies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Off-label use of drugs
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Shifting focus on new drug modalities
    • 5.2.3.2 Rapidly expanding market in developing countries
    • 5.2.3.3 Need to address dry age-related macular degeneration and geographic atrophy
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Non-adherence to treatments
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Hybridoma technology
    • 5.3.1.2 Recombinant DNA technology
    • 5.3.1.3 Antibody engineering
  • 5.3.2 ADJACENT TECHNOLOGIES
    • 5.3.2.1 Tissue engineering (scaffold technology)
    • 5.3.2.2 Artificial intelligence
    • 5.3.2.3 Optogenetic technology
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE)
  • 5.5.2 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION
  • 5.5.3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 SUPPLY CHAIN ANALYSIS
• 5.8 ECOSYSTEM ANALYSIS
• 5.9 PATENT ANALYSIS
• 5.10 REGULATORY ANALYSIS
  • 5.10.1 REGULATORY LANDSCAPE
    • 5.10.1.1 US
    • 5.10.1.2 Europe
    • 5.10.1.3 Emerging economies
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11.2 BARGAINING POWER OF SUPPLIERS
  • 5.11.3 BARGAINING POWER OF BUYERS
  • 5.11.4 THREAT OF SUBSTITUTES
  • 5.11.5 THREAT OF NEW ENTRANTS
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 BUYING CRITERIA
• 5.14 INVESTMENT/FUNDING ACTIVITY
• 5.15 PIPELINE ANALYSIS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED MACULAR DEGENERATION TREATMENT
  • 5.16.2 ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED MACULAR DEGENERATION TREATMENT
  • 5.16.3 HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT
• 5.17 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET

6 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 EYLEA & EYLEA HD
  • 6.2.1 HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS TO SPEED UP GROWTH
• 6.3 LUCENTIS
  • 6.3.1 PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL THICKNESS TO FAVOR GROWTH
• 6.4 VABYSMO
  • 6.4.1 FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES TO SUSTAIN GROWTH
• 6.5 SYFOVRE
  • 6.5.1 INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED MACULAR DEGENERATION TO BOOST MARKET
• 6.6 OTHER PRODUCTS

7 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE

• 7.1 INTRODUCTION
• 7.2 AFLIBERCEPT
  • 7.2.1 HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS TO EXPEDITE GROWTH
• 7.3 FARICIMAB
  • 7.3.1 FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH STUDIES TO AUGMENT GROWTH
• 7.4 RANIBIZUMAB
  • 7.4.1 ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET
• 7.5 PEGCETACOPLAN
  • 7.5.1 HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO CONTRIBUTE TO GROWTH
• 7.6 OTHER MOLECULES

8 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE

• 8.1 INTRODUCTION
• 8.2 BIOLOGICS
  • 8.2.1 HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES TO SUPPORT GROWTH
• 8.3 BIOSIMILARS
  • 8.3.1 LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH

9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD

• 9.1 INTRODUCTION
• 9.2 WET AMD
  • 9.2.1 GROWING GERIATRIC POPULATION TO FACILITATE GROWTH
• 9.3 DRY AMD
  • 9.3.1 INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH

10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
• 10.4 SPECIALTY CENTERS
  • 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH

11 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising investment in healthcare research & development to propel market
  • 11.2.3 CANADA
    • 11.2.3.1 Favorable government initiatives to aid market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising focus on clinical research with public-private partnerships to augment growth
  • 11.3.3 UK
    • 11.3.3.1 Ongoing technological advancements to promote growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing investments in funding healthcare and allied technology to foster growth
  • 11.3.5 ITALY
    • 11.3.5.1 Comprehensive treatment coverage and funding for new therapies to fuel market
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing number of collaborative projects to favor market growth
  • 11.3.7 NETHERLANDS
    • 11.3.7.1 Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Strategic drug approvals to support market growth
  • 11.4.3 JAPAN
    • 11.4.3.1 Advanced healthcare infrastructure to encourage growth
  • 11.4.4 INDIA
    • 11.4.4.1 Regulatory reforms and aging population to boost market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increasing disease incidence and evolving treatment options to facilitate growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Supportive regulatory environment to boost market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Increasing rate of visual impairment to sustain growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Sustained health coverage and biosimilar drug approvals to propel market
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Increasing focus on technological advancements, ongoing research, and government initiatives to support growth
    • 11.6.2.3 Other GCC Countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
• 12.3 REVENUE ANALYSIS, 2021-2023
• 12.4 MARKET SHARE ANALYSIS, 2023
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Molecule footprint
    • 12.5.5.3 Approval footprint
    • 12.5.5.4 Type of AMD footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.7.1 COMPANY VALUATION
  • 12.7.2 FINANCIAL METRICS
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 F. HOFFMANN-LA ROCHE LTD
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches & approvals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 REGENERON PHARMACEUTICALS INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches & approvals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 NOVARTIS AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product launches & approvals
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 BAYER AG
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches & approvals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 APELLIS PHARMACEUTICALS
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches & approvals
      • 13.1.5.3.2 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
        • 13.1.5.4.2.1 Weaknesses and competitive threats
  • 13.1.6 ASTELLAS PHARMA INC.
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product launches & approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 STADA ARZNEIMITTEL AG
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches & approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 BIOGEN
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches & approvals
  • 13.1.9 FORMYCON AG
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product launches & approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 COHERUS BIOSCIENCES
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Products launches & approvals
      • 13.1.10.3.2 Other developments
  • 13.1.11 BIOCON
    • 13.1.11.1 Business overview
    • 13.1.11.2 Product offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product launches & approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 OUTLOOK THERAPEUTICS, INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches & approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches & approvals
      • 13.1.13.3.2 Deals
  • 13.1.14 INTAS PHARMACEUTICALS LTD.
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
  • 13.1.15 SANDOZ GROUP AG
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches & approvals
      • 13.1.15.3.2 Deals
      • 13.1.15.3.3 Expansions
  • 13.1.16 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 OCULAR THERAPEUTIX, INC.
  • 13.2.2 OPTHEA LIMITED
  • 13.2.3 KODIAK SCIENCES INC.
  • 13.2.4 BIO-THERA
  • 13.2.5 AMGEN INC.
  • 13.2.6 ALVOTECH
  • 13.2.7 STEALTH BIOTHERAPEUTICS INC.
  • 13.2.8 ALTEOGEN INC.
  • 13.2.9 OCUMENSION THERAPEUTICS
  • 13.2.10 INNOVENT
  • 13.2.11 SHANGHAI HENLIUS BIOTECH, INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS